Media headlines about Arbutus Biopharma Corporation (NASDAQ:ABUS) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arbutus Biopharma Corporation earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.2460312878611 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of research firms have recently commented on ABUS. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma Corporation in a report on Monday, August 7th. Wedbush reissued an “outperform” rating and set a $9.00 price target on shares of Arbutus Biopharma Corporation in a report on Wednesday, September 20th. Leerink Swann reissued a “market perform” rating and set a $5.00 price target (up previously from $4.00) on shares of Arbutus Biopharma Corporation in a report on Tuesday, November 7th. ValuEngine raised Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. Finally, Zacks Investment Research raised Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $13.00.
Arbutus Biopharma Corporation (ABUS) opened at $5.85 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 11.03 and a current ratio of 11.03. Arbutus Biopharma Corporation has a fifty-two week low of $2.35 and a fifty-two week high of $8.25.
In other news, insider Michael J. Sofia sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $8.00, for a total transaction of $80,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.00% of the stock is currently owned by insiders.
WARNING: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/24/arbutus-biopharma-corporation-abus-receives-news-sentiment-score-of-0-16.html.
Arbutus Biopharma Corporation Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.